ICON Public (NASDAQ:ICLR) Releases FY25 Earnings Guidance

ICON Public (NASDAQ:ICLR) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $13.00-15.00 for the period, compared to the consensus estimate of $14.86. The company issued revenue guidance of $8.05-8.65 billion, compared to the consensus revenue estimate of $8.50 billion. ICON Public also updated its FY24 guidance to $13.90-14.10 EPS.

ICON Public Stock Performance

Shares of NASDAQ:ICLR opened at $217.99 on Tuesday. The firm has a market capitalization of $17.98 billion, a PE ratio of 24.30, a P/E/G ratio of 1.54 and a beta of 1.20. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The business’s 50 day moving average price is $211.31 and its 200-day moving average price is $270.81. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. ICON Public’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 EPS. As a group, equities research analysts expect that ICON Public will post 13.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ICLR. Royal Bank of Canada assumed coverage on shares of ICON Public in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $263.00 price target for the company. The Goldman Sachs Group decreased their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Redburn Atlantic initiated coverage on ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price on the stock. Leerink Partners reissued an “outperform” rating and set a $255.00 price target (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Finally, Robert W. Baird reduced their target price on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.